MC
EGRX

Maverick Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Maverick Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,301
Closed -$263K – 880
2021
Q1 		$263K Buy
+6,301
New +$293K ﹤0.01% 460

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Maverick Capital's EGRX Position: Q2 2021 in Review

Maverick Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 6,301 shares — an estimated $263K sold.

Maverick Capital first reported a position in EGRX in Q1 2021 and held it in 1 quarter. The position peaked at $263K in Q1 2021. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

  • Maverick Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Maverick Capital sold 6,301 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $263K.
  • Maverick Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Maverick Capital's Eagle Pharmaceuticals, Inc. position peaked at $263K in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.